1. P215 Blood-based prognostic biomarkers in Crohn's patients treated with biologics: a new promising tool to predict endoscopic outcomes. (27th May 2021) Authors: Grova, M; Crispino, F; Maida, M; Renna, S; Mocciaro, F; Casà, A; Rizzuto, G; Scimeca, D; Di Mitri, R; Macaluso, F S; Orlando, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S272 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). (27th May 2021) Authors: Macaluso, F; Fries, W; Renna, S; Viola, A; Muscianisi, M; Cappello, M; Guida, L; Siringo, S; Camilleri, S; Garufi, S; Privitera, A C; Belluardo, N; Giangreco, E; Bertolami, C; Vassallo, R; Rizzuto, G; Orlando, R; Ventimiglia, M; Orlando, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn's disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD). (15th January 2020) Authors: Macaluso, F S; Ventimiglia, M; Fries, W; Viola, A; Sitibondo, A; Cappello, M; Scrivo, B; Busacca, A; Privitera, A C; Camilleri, S; Garufi, S; Di Mitri, R; Mocciaro, F; Belluardo, N; Giangreco, E; Bertolami, C; Renna, S; Orlando, R; Rizzuto, G; Cottone, M Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P347 Sarcopenia is a poor prognostic factor for endoscopic outcomes in patients with Crohn's disease. (21st January 2022) Authors: Grova, M; Crispino, F; Maida, M; Vitello, A; Tesè, L; Rizzuto, G; Casà, A; Renna, S; Macaluso, F S; Orlando, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. (27th May 2021) Authors: Macaluso, F; Cappello, M; Busacca, A; Fries, W; Viola, A; Costantino, G; Magnano, A; Vinci, E; Ferracane, C; Privitera, A C; Piccillo, G; Belluardo, N; Giangreco, E; Romano, C; Citrano, M; Graziano, F; Garufi, S; Bertolami, C; Scrivo, B; Renna, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S437 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P644 Effectiveness of vedolizumab on intestinal outcomes and articular manifestations: Real-world data from the Sicilian Network for inflammatory bowel disease (SN-IBD). (16th January 2018) Authors: Macaluso, F S; Orlando, R; Fries, W; Scolaro, M; Magnano, A; Pluchino, D; Cappello, M; Morreale, G C; Siringo, S; Privitera, A C; Ferracane, C; Belluardo, N; Alberghina, N; Ventimiglia, M; Rizzuto, G; Renna, S; Cottone, M; Orlando, A Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P703 The real-world long-term effectiveness of vedolizumab in inflammatory bowel diseases: a single-centre observational study. (25th January 2019) Authors: Macaluso, F S; Croce, A; Orlando, R; Ventimiglia, M; Sapienza, C; Gambino, F; Orlando, E; Grova, M; Rizzuto, G; Renna, S; Cottone, M; Orlando, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P737 SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis. (25th January 2019) Authors: Macaluso, F S; Cappello, M; Giuffrida, E; Fries, W; Centritto, A; Privitera, A C; Inserra, G; Vassallo, R; Magnano, A; Vinci, E; Garufi, S; Ventimiglia, M; Renna, S; Orlando, R; Rizzuto, G; Cottone, M; Orlando, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S490 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗